Frontline Pola-R-CHP, CAR T-Cell Second-line Therapies Are Not Cost-effective in DLBCLFebruary 7th 2023
An economic analysis showed that neither polatuzumab vedotin-piiq added to standard of care chemotherapy nor CD19-directed chimeric antigen receptor T-cell therapy is likely to be the most cost-effective for patients with diffuse large B-cell lymphoma.
Investigators Seek Simpler Solution to Treatment Resistance in Esophageal CancerFebruary 6th 2023
Although the incidence, location, and histology of esophageal cancer vary globally, patients in the Western World typically develop esophageal cancer in the distal esophagus or at the gastroesophageal junction.
MOUNTAINEER-03 Propels Progress in Metastatic HER2+ CRCFebruary 3rd 2023
The MOUNTAINEER-03 trial is designed to evaluate the efficacy of tucatinib and trastuzumab plus modified leucovorin calcium, fluorouracil, and oxaliplatin, compared with standard-of-care, first-line therapy for metastatic HER2-positive colorectal cancer.
Breast Cancer Expert Focuses on Decoding BiomarkersFebruary 2nd 2023
For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.
Neoadjuvant Therapy Helps Shape Changing Landscape of Early-Stage NSCLCFebruary 1st 2023
The treatment of patients with early-stage non–small cell lung cancer is rapidly evolving across the spectrum of care, particularly in the neoadjuvant setting, where evidence in favor of systemic chemoimmunotherapy regimens is growing.
Exploring the Nuances of Regulatory Approval Vs Optimal Use of a New Antineoplastic AgentJanuary 31st 2023
Accelerated regulatory approvals in the past 10 to 15 years, both of novel drugs and their use as part of newer strategies present a challenge to relatively simple drug development and clinical use paradigms.